Again, CHK1 inhibitors (specifically the compounds AZD-7762 and CHIR124), together with the WEE1 inhibitor adavosertib, were among the kinase inhibitors displaying the best activity in combination with BRAF inhibitors (dabrafenib and vemurafenib) in a kinase inhibitor library screening, recently conducted in BRAF mutated melanoma cell lines (sensitive or made resistant to BRAF inhibitors) [71]. The gene discussed is CHEK1; the disease is melanoma.